High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004

AIDS

Volumn 21, Issue 15, 2007, Pages 2103-2106

  Paredes, Roger ^a,b   Cheng, Irene ^c   Kuritzkes, Daniel R ^a   Tuomala, Ruth E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Clinical Trials & Surveys Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 34648831474     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282ef3822     Document Type: Article

References (10)

1. Shah SS, Crane M, Monaghan K, McGowan JP. Genotypic resistance testing in HIV-infected pregnant women in an urban setting. Int J STD AIDS 2004; 15:384-387.
2. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67.
3. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet 1994; 344:1771-1772.
4. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-110.
5. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:5653-5656.
6. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 177:1533-1540.
7. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
8. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Meth 2007. In press.
9. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, Pitt J, for the Women and Infants Transmission Study. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York city during 1991 to early 2001. J Acquir Immune Defic Syndr 2007; 44:329-335.
10. Johnson JA, Li J-F, Wei X, Craig C, Stone C, Horton JH, et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1-infected persons. In: XVth International Drug Resistance Workshop, Basic Principles and Clinical Implications. Sitges, Spain. 13-17 June 2006.